Longeveron (LGVN) Share-based Compensation Growth (1y) (2021 - 2026)
Longeveron (LGVN) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 11.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.47% |
| Dec 31, 2025 | -3.59% |
| Sep 30, 2025 | -68.29% |
| Jun 30, 2025 | 123.04% |
| Mar 31, 2025 | 15.25% |
| Dec 31, 2024 | -5.57% |
| Sep 30, 2024 | 183.17% |
| Jun 30, 2024 | -67.10% |
| Mar 31, 2024 | -29.93% |
| Dec 31, 2023 | -36.07% |
| Sep 30, 2023 | -0.20% |
| Jun 30, 2023 | -22.33% |
| Mar 31, 2023 | -14.26% |
| Dec 31, 2022 | -89.49% |
| Sep 30, 2022 | -79.97% |
| Jun 30, 2022 | -59.44% |
| Mar 31, 2022 | 312.61% |
| Dec 31, 2021 | 204,700.00% |
| Sep 30, 2021 | 19,100.00% |
| Jun 30, 2021 | 20,072.73% |